Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Background: Although the OCN (omeprazole, clarithromycin and nitroimidazoles) short-term low-dose regimens are regarded as 'the standard' in the treatment of Helicobacter pylori infection, azithromycin is a new-generation, acid-stable macrolide which may prove particularly useful for a new short-ter...
| Publicado en: | European Journal of Gastroenterology & Hepatology Vol. 9; no. 1; pp. 45 - 49 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Jan1997
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110641103&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 110641103 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0954691X 8CE jtl: European Journal of Gastroenterology & Hepatology issn: 0954691X maglogo: N pubinfo: dt: Jan1997 vid: 9 iid: 1 pid: 5086 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 110641103 110641103 NLM9031898 110641103 10.1097/00042737-199701000-00012 NLM9031898 110641103 ppf: 45 ppct: 4 formats: tig: atl: Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. aug: au: Caselli, Michele Trevisani, Lucio Tursi, Antonio Sartori, Sergio Ruina, Marco Luzzi, Ida Gaudenzi, Piergiorgio Alvisi, Vittorio Gasbarrini, Giovanni Caselli, M Trevisani, L Tursi, A Sartori, S Ruina, M Luzzi, I Gaudenzi, P Alvisi, V Gasbarrini, G affil: School of Gastroenterology, University of Ferrara, Italy sug: subj: Helicobacter Pylori Antibiotics Therapeutic Use Omeprazole Azithromycin Therapeutic Use Helicobacter Infections Drug Therapy Metronidazole Therapeutic Use Peptic Ulcer Microbiology Helicobacter Infections Etiology Omeprazole Economics Cost Benefit Analysis Endoscopy, Digestive System Azithromycin Administration and Dosage Omeprazole Administration and Dosage Metronidazole Economics Sulfur Compounds Omeprazole Therapeutic Use Helicobacter Infections Pathology Middle Age Metronidazole Administration and Dosage Prospective Studies Biopsy Administration, Oral Adult Gastritis Microbiology Human Aged Antibiotics Economics Female Antibiotics Administration and Dosage Male Azithromycin Economics Lansoprazole Treatment Outcomes Duodenal Ulcer Microbiology Dose-Response Relationship, Drug Clinical Trials Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Middle Aged: 45-64 years Adult: 19-44 years Aged: 65+ years Female Male ab: Background: Although the OCN (omeprazole, clarithromycin and nitroimidazoles) short-term low-dose regimens are regarded as 'the standard' in the treatment of Helicobacter pylori infection, azithromycin is a new-generation, acid-stable macrolide which may prove particularly useful for a new short-term low-dose triple therapy regimen.Objective: To further improve OCN eradication treatments by reducing both the number of pills and the total cost.Methods: A new short-term low-dose triple therapy (LAM) using lansoprazole 30 mg once a day for 1 week, azithromycin 500 mg once a day for 3 days, and metronidazole 250 mg twice a day for the same 3 days, was administrated to 60 patients presenting with H. pylori-positive gastritis with or without peptic ulcer, and compared with the classic 'Bazzoli regimen' (OCT: omeprazole, clarithromycin, tinidazole) in 60 matched patients. H. pylori infection before and after therapy was evaluated by a rapid urease test, conventional histology and toluidine-stained semi-thin sections. Three biopsies from the corpus and three from the antrum were taken during endoscopical examination before and 7-8 weeks after discontinuation of the treatment. Patient compliance, drug tolerance and drug costs were also taken into consideration.Results: H. pylori infection was eradicated 7-8 weeks after treatment in 56 of the 60 patients in the LAM group (93.3%), and in 52 of the 57 patients in the OCT group who completed the treatment (91.2%), with no statistical difference. When gastric or duodenal ulceration was present, ulcer healing was observed in all cases.Conclusion: The new proposed short-term low-dose triple therapy (LAM) appears to be as effective as the OCT for the eradication of H. pylori infection. The new treatment, however, seems to have advantages in terms of drug tolerance, patient compliance and therapy cost. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|